Palisade Bio, Inc.: Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibroste ...

Palisade Flat on Crohn’s Investment

Palisade Bio, Inc. (NASDAQ: PALI) shares barely cleared breakeven Wednesday. The company, a clinical-stage biopharmaceutical concern developing next-generation, once-daily, oral PDE4 inhibitor ...

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and ...